Tirzepatide Reduces 24-Hour Ambulatory Blood Pressure in Adults With Body Mass Index ≥27 kg/m²: SURMOUNT-1 Ambulatory Blood Pressure Monitoring Substudy

Hypertension. 2024 Apr;81(4):e41-e43. doi: 10.1161/HYPERTENSIONAHA.123.22022. Epub 2024 Feb 5.

Affiliations

¹ Cardiovascular Division, University of Texas Southwestern Medical Center, Dallas (J.A.d.L., W.V.).
² Eli Lilly and Company, Indianapolis, IN (B.L., L.F., A.H., N.N.A., M.C.B., A.S.).
³ Diabetes Complications Research Centre, Conway Institute, University College Dublin, Ireland (C.W.l.R.).
⁴ Cleveland Clinic Foundation, Department of Cardiovascular Medicine, Cleveland, OH (L.J.L.).

No abstract available

Keywords: blood pressure; gastric inhibitory polypeptide; glucagon-like peptide 1; hypertension; obesity; risk factors.

Publication types

Letter

MeSH terms

Adult
Blood Pressure / physiology
Blood Pressure Monitoring, Ambulatory
Body Mass Index
Diabetes Mellitus, Type 2*
Gastric Inhibitory Polypeptide*
Glucagon-Like Peptide-1 Receptor
Glucagon-Like Peptide-2 Receptor*
Humans
Hypertension* / diagnosis
Hypertension* / drug therapy
Hypoglycemic Agents

Substances

tirzepatide
Hypoglycemic Agents
Glucagon-Like Peptide-1 Receptor
Glucagon-Like Peptide-2 Receptor
Gastric Inhibitory Polypeptide